(Q36795957)

16 August 2017

Immune therapy and β-cell death in type 1 diabetes (English)

1 reference

16 August 2017

0 references

1 reference

1 reference

10

Kevan C Herold

1 reference

16 August 2017

Jasmin Lebastchi

1

1 reference

16 August 2017

Songyan Deng

2

1 reference

16 August 2017

Amir H Lebastchi

3

1 reference

16 August 2017

Isabel Beshar

4

1 reference

16 August 2017

Stephen Gitelman

5

1 reference

16 August 2017

Steven Willi

6

1 reference

16 August 2017

Peter Gottlieb

7

1 reference

16 August 2017

Eitan M Akirav

8

1 reference

16 August 2017

Jeffrey A Bluestone

9

1 reference

16 August 2017

language of work or name

English

0 references

publication date

19 February 2013

1 reference

16 August 2017

5

1 reference

inferred from page(s)

published in

Diabetes

1 reference

16 August 2017

62

1 reference

16 August 2017

5

1 reference

16 August 2017

1676-1680

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

16 August 2017

start time

8 September 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Detection of β cell death in diabetes using differentially methylated circulating DNA.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Genetics, pathogenesis and clinical interventions in type 1 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

DNA demethylation in hormone-induced transcriptional derepression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Insulin gene expression is regulated by DNA methylation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Autophagy regulates pancreatic beta cell death in response to Pdx1 deficiency and nutrient deprivation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Proinsulin/C-peptide ratio, glucagon and remission in new-onset Type 1 diabetes mellitus in young adults.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3636605

Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23423576

12 December 2020

inferred from PubMed ID database lookup

Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23423576

12 December 2020

inferred from PubMed ID database lookup

IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23423576

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.2337/DB12-1207

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

23423576

1 reference